BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $268,000 | -44.4% | 3,456 | -38.5% | 0.03% | -41.3% |
| Q4 2021 | $482,000 | +6.6% | 5,619 | 0.0% | 0.05% | -2.1% |
| Q3 2021 | $452,000 | -9.6% | 5,619 | -9.5% | 0.05% | -7.8% |
| Q2 2021 | $500,000 | -6.4% | 6,209 | -2.0% | 0.05% | -12.1% |
| Q1 2021 | $534,000 | +5.1% | 6,334 | 0.0% | 0.06% | 0.0% |
| Q4 2020 | $508,000 | -13.5% | 6,334 | -13.2% | 0.06% | -21.6% |
| Q3 2020 | $587,000 | -7.4% | 7,301 | -0.9% | 0.07% | -11.9% |
| Q2 2020 | $634,000 | +5.5% | 7,366 | -0.4% | 0.08% | -8.7% |
| Q1 2020 | $601,000 | -10.2% | 7,398 | -7.5% | 0.09% | +13.6% |
| Q4 2019 | $669,000 | -4.4% | 7,998 | 0.0% | 0.08% | -12.0% |
| Q3 2019 | $700,000 | +7.4% | 7,998 | +0.4% | 0.09% | +5.7% |
| Q2 2019 | $652,000 | -6.3% | 7,966 | -6.8% | 0.09% | -5.4% |
| Q1 2019 | $696,000 | -1.0% | 8,551 | -20.0% | 0.09% | -1.1% |
| Q4 2018 | $703,000 | -15.2% | 10,684 | -0.7% | 0.09% | -1.1% |
| Q3 2018 | $829,000 | +4.4% | 10,754 | +0.1% | 0.09% | -1.1% |
| Q2 2018 | $794,000 | -7.9% | 10,744 | -18.9% | 0.10% | -9.5% |
| Q1 2018 | $862,000 | -2.2% | 13,249 | -2.7% | 0.10% | -1.9% |
| Q4 2017 | $881,000 | +4.0% | 13,618 | +0.9% | 0.11% | -4.5% |
| Q3 2017 | $847,000 | +14.6% | 13,492 | +10.5% | 0.11% | +5.7% |
| Q2 2017 | $739,000 | +17.9% | 12,212 | +1.1% | 0.11% | +12.8% |
| Q1 2017 | $627,000 | +63.3% | 12,074 | +39.1% | 0.09% | +38.2% |
| Q4 2016 | $384,000 | -9.6% | 8,677 | -2.8% | 0.07% | -10.5% |
| Q3 2016 | $425,000 | -8.8% | 8,924 | -13.4% | 0.08% | -9.5% |
| Q2 2016 | $466,000 | 0.0% | 10,309 | -9.1% | 0.08% | +1.2% |
| Q1 2016 | $466,000 | +5.9% | 11,344 | -1.7% | 0.08% | +5.1% |
| Q4 2015 | $440,000 | -3.7% | 11,544 | -17.1% | 0.08% | -10.2% |
| Q3 2015 | $457,000 | -89.8% | 13,924 | -78.4% | 0.09% | -88.8% |
| Q2 2015 | $4,499,000 | -1.4% | 64,344 | -3.4% | 0.79% | -4.0% |
| Q1 2015 | $4,562,000 | -2.4% | 66,594 | +4.4% | 0.82% | -4.8% |
| Q4 2014 | $4,676,000 | +2.4% | 63,804 | +0.3% | 0.86% | +1.3% |
| Q3 2014 | $4,567,000 | +5.8% | 63,644 | +6.6% | 0.85% | +17.9% |
| Q2 2014 | $4,316,000 | -1.5% | 59,699 | +0.2% | 0.72% | -3.2% |
| Q1 2014 | $4,382,000 | +15.9% | 59,559 | +9.5% | 0.74% | +18.4% |
| Q4 2013 | $3,782,000 | +17090.9% | 54,372 | +16376.4% | 0.63% | +15625.0% |
| Q3 2013 | $22,000 | -4.3% | 330 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $23,000 | – | 330 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |